Australia: Federal Court of Australia dismisses preliminary discovery application regarding biosimilar suspected of infringing manufacturing process patents

Last Updated: 26 March 2017
Article by Duncan Longstaff and Jacinta Flattery-O'Brien

In the recent decision of Pfizer Ireland Pharmaceuticals v Samsung Bioepis AU Pty Ltd [2017] FCA 285 (21 March 2017), Justice Stephen Burley of the Federal Court of Australia has delivered an important decision dismissing an application for preliminary discovery of documents relevant to determining whether a registered biosimilar product might infringe one or more patents claiming manufacturing processes.


Pfizer parties (collectively, Pfizer) were concerned that Samsung Bioepis Co Ltd Korea (SBK) and Samsung Bioepis AU Pty Ltd (SBA) were infringing one or more of their registered patents claiming a process for making a biological medicine, etanercept. Pfizer therefore sought orders pursuant to r 7.23 of the Federal Court Rules 2011 (Cth) for preliminary discovery of confidential documents lodged with the Therapeutic Goods Administration (TGA) in order to determine whether to commence proceedings against SBK and SBA for patent infringement.

Etanercept is the active ingredient in ENBREL, a biological medicine used in the treatment of autoimmune diseases sponsored in Australia by Pfizer Australia Pty Ltd. Until recently, it has been the only product containing etanercept registered on the Australian Register of Therapeutic Goods. In 2016, SBA sponsored the registration of two pharmaceutical products containing etanercept as their active ingredient and both have been registered on the ARTG under the name of BRENZYS. The parties agreed that BRENZYS were developed as a biosimilar to ENBREL, meaning that it is almost an identical copy of an original product that is manufactured by a different company. The TGA guidelines require that biosimilars must satisfy an extensive comparability exercise with the chosen reference medicinal product to ensure similar quality, safety and efficacy. However, Burley J noted that simply because BRENZYS and ENBREL were biosimilars does not conclusively determine that the process used to manufacture the products is the same.


Burley J accepted that through a chain of correspondence with the respondents, Pfizer had made reasonable inquiries and did not have sufficient information to decide whether to commence proceedings, as required by FCR 7.23(1)(b). On this note Burley J confirmed that it is sufficient for a prospective applicant to broadly provide the basis on which it forms the views that it holds and makes inquiries of parties from whom it might reasonably be expected that relevant information may be obtained. Burley J specifically observed that Pfizer's offer of a confidentiality regime confining access to the requested documents assisted it in establishing the reasonableness of its inquiries.

The main issue for determination was whether Pfizer had the requisite subjective and objective reasonable belief that it had the right to obtain relief for patent infringement from SBA in accordance with FCR 7.23(1)(a). There was no dispute that Pfizer had demonstrated the requisite subjective belief. However, the substantive debate was whether there was an objective basis. Pfizer reasoned that BRENZYS had a peculiar level of similarity to ENBREL and that because of the complexity of the products the similarity inferred that the process to make each product must be similar. Further, because Pfizer contended (without adducing direct evidence) that the process by which it manufactures ENBREL falls within the scope of the claims in question, the process by which SBK manufactures BRENZYS must therefore also fall within the scope of the claims. Nonetheless, Burley J held that this chain of reasoning did not rise above speculation. Accordingly, Pfizer failed to demonstrate a reasonable objective belief that they have the right to obtain relief for patent infringement from SBA in accordance with FCR 7.23(1)(a).

Further, Burley J found that even if Pfizer had established the requisite reasonable belief, he would have exercised the judicial discretion conferred by FCR 7.32(2) against granting the preliminary discovery order sought. Burley J noted in particular the scope of the documents sought and the fact that Pfizer did not adduce evidence of its own manufacturing process for ENBREL.


This decision of Burley J to dismiss Pfizer's application for preliminary discovery begs the question of how the patentee of a patent claiming a process or method of producing a product, rather than the product itself or a method of using it after it has been made and entered the market (eg, in a method of treatment), can obtain the information necessary to elevate suspicions of infringement to the requisite level of belief to commence court proceedings.

The issue is particularly stark in the context of biosimilars and generic pharmaceuticals, where associated regulatory requirements mean the allegedly infringing products are relevantly equivalent (and possibly identical) to at least the patentee's own approved products (which patentees will contend embody the inventions of one or more of their patents). The confidential nature of regulatory applications such as those made to the TGA mean the only parties with access to documents which set out the manufacturing processes for the subject products are the product sponsor and the TGA itself. The likely futility of seeking the information or documents from the TGA under the Freedom of Information Act 1982 (Cth) (see: Secretary Department of Health and Ageing v iNova Pharmaceuticals (Australia) Pty Limited [2010] FCA 1442 (21 December 2010)) means that a patentee's only practical option is to seek the information required to form a view on infringement of its patents from the alleged infringer itself – either voluntarily through correspondence, or under the compulsion of a court order for preliminary discovery.

From this perspective, Burley J's decision that Pfizer had not satisfied the requirements for a preliminary discovery order appears harsh – particularly where it was clear the sought information and documents existed and access could have been confined to Pfizer's external solicitors subject to a strict confidentiality regime. However, the critical aspect underpinning Burley J's decision appears to have been that Pfizer needed to, but did not, adduce evidence regarding the processes by which its own products were produced, which would have established whether or not those processes embodied the inventions of one or more of its three patents. That is, Pfizer effectively needed to provide quid pro quo by giving the Court and SBA's external lawyers confidential access to details of its own production processes, as this could have resolved many of the uncertainties and assumptions underpinning its objective reason to believe. Although such an approach by Pfizer may not have led to a different outcome on its preliminary discovery application, it does appear that any patentee seeking such an order to establish infringement of patents claiming production processes should be prepared to adduce evidence of its own production processes, at least to the Court and the other party's external solicitors.

Pfizer has until mid-April 2017 to lodge any appeal from Burley J's decision. However, BRENZYS (to be marketed and distributed by Merck Sharp & Dohme) will be listed on the PBS, triggering price drop implications (initially 16%) for ENBREL, from 1 April 2017. Therefore, even it does successfully appeal this decision and ultimately obtain preliminary discovery of documents which provide sufficient information to sue SBK and SBA for patent infringement, Pfizer's opportunity to obtain an effective interlocutory injunction restraining BRENZYS and protecting the PBS price of ENBREL appears to have passed.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Shelston IP ranked one of Australia's leading Intellectual Property firms in 2015.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Duncan Longstaff
Jacinta Flattery-O'Brien
Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.